The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera

Blood

Volumn 108, Issue 6, 2006, Pages 1865-1867

  Lippert, Eric ^b   Boissinot, Marjorie ^b   Kralovics, Robert ^b   Girodon, François ^b   Dobo, Irène ^b   Praloran, Vincent ^b   Boiret Dupré, Nathalie ^b   Skoda, Radek C ^b   Hermouet, Sylvie ^a  

^a INSTITUT DE BIOLOGIE   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DNA; JANUS KINASE 2; MESSENGER RNA;

ARTICLE; CELL LINEAGE; CONTROLLED STUDY; CORRELATION ANALYSIS; ERYTHROCYTOSIS; GENE EXPRESSION; GENE FREQUENCY; GENE MUTATION; GRANULOCYTE; HEMATOPOIETIC CELL; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; PHENOTYPE; POLYCYTHEMIA VERA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; THROMBOCYTHEMIA; THROMBOCYTOSIS; WILD TYPE;

EID: 33748684367     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-01-013540     Document Type: Article

References (19)

1. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434:1144-1148.
2. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352:1779-1790.
3. Baxter EJ, Scott LM, Campbell PJ, et al. Cancer Genome Project: acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054-1061.
4. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7:387-397.
5. Cazzola M, Skoda RC. Gain of function, loss of control: a molecular basis for chronic myeloproliferative disorders. Haematologica. 2005;90:871-874.
6. Goerttler PS, Steimle C, Märze E, et al. The JAK2 V617F mutation, PRV-1 overexpression, and EEC formation define a similar cohort of MPD patients. Blood. 2005;106:2862-2864.
7. Tefferi A, Sirhan S, Lasho TL, et al. Concomitant neutrophil JAK2 mutation screening and PRV-1 expression analysis in myeloproliferative disorders and secondary polycythemia. Br J Haematol. 2005;131:166-171.
8. Campbell PJ, Scott LM, Buck G, et al. Definition of subtypes of essential thrombocythaemia and relation to polycythemia vera based on JAK2 V617F mutation status: a prospective study. Lancet. 2005;366:1945-1953.
9. Dobo I, Boiret N, Lippert E, et al. A standardized endogenous megakaryocytic/erythroid (EMC/EEC) colony assay for the diagnosis of essential thrombocythemia. Haematologica. 2004;89:1203-1208.
10. Dobo I, Donnard M, Girodon F, et al. Standardization and comparison of endogenous erythroid colony assay performed with bone marrow or blood progenitors for the diagnosis of polycythaemia vera. Hematol J. 2004;5:161-167.
11. Dobo I, Mossuz P, Campos L, et al. Comparison of four serum-free, cytokine-free media for the analysis of endogenous erythroid colony (EEC) growth in polycythemia vera (PV) and essential thrombocythemia (ET). Hematol J. 2001;2:396-403.
12. Mossuz P, Girodon F, Donnard M, et al. Diagnostic value of serum erythropoietin level in patients with absolute erythrocytosis. Haematologica. 2004;89:1194-1198.
13. Klippel S, Strunck E, Temerinac S, et al. Quantification of PRV-1 mRNA distinguishes polycythemia vera from secondary erythrocytosis. Blood. 2003;102:3569-3574.
14. Beillard E, Pallisgaard N, Van Der Velden VH, et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RTPCR): a Europe against cancer program. Leukemia. 2003;17:2474-2486.
15. Michiels JJ, Juvonen E. Proposal for revised diagnostic criteria of essential thrombocythemia and polycythemia vera by the Thrombocythemia Vera Study Group. Semin Thrombosis Hemostasis. 1997;23:339-347.
16. Pierre R, Imbert M, Thiele J, et al. Chronic myeloproliferative diseases. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organization (WHO) Classification of Tumours: Pathology and Genetics of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001:15-44.
17. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100:2292-2302.
18. Levine RL, Belisle C,Wadleigh M, et al. X-inactivation based clonality analysis and quantitative JAK2V617F assessment reveals a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F negative ET and MMM patients with clonal hematopoiesis. Blood. 2006;107:4139-4141.
19. Kralovics R, Teo SS, Buser AS, et al. Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2. Blood. 2005;106:3374-3376.